{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:02:54Z","timestamp":1787166174025,"version":"build-2736575974"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.psychres.2020.113641","type":"journal-article","created":{"date-parts":[[2020,12,13]],"date-time":"2020-12-13T02:01:21Z","timestamp":1607824881000},"page":"113641","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An update on management of behavioral and psychological symptoms in dementia"],"prefix":"10.1016","volume":"295","author":[{"given":"Anderson","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Copeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7665-4540","authenticated-orcid":false,"given":"Eran","family":"Metzger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alesia","family":"Cloutier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9477-241X","authenticated-orcid":false,"given":"David N.","family":"Osser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.psychres.2020.113641_bib0001","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/HRP.0000000000000098","article-title":"The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An Algorithm for Generalized Anxiety Disorder","volume":"24","author":"Abejuela","year":"2016","journal-title":"Harv Rev Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2020.113641_bib0002","article-title":"The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease","author":"Ballard","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.psychres.2020.113641_bib0003","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.13r08672","article-title":"Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation","volume":"75","author":"Beach","year":"2014","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.psychres.2020.113641_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2019.112583","article-title":"The psychopharmacology algorithm project at the Harvard South Shore Program: An algorithm for adults with obsessive-compulsive disorder","volume":"281","author":"Beaulieu","year":"2019","journal-title":"Psychiatry Res"},{"issue":"8","key":"10.1016\/j.psychres.2020.113641_bib0005","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11920-019-1049-5","article-title":"Management of Behavioral and Psychological Symptoms of Dementia","volume":"21","author":"Bessey","year":"2019","journal-title":"Curr Psychiatry Rep"},{"issue":"9","key":"10.1016\/j.psychres.2020.113641_bib0006","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1176\/appi.ajp.2012.11101529","article-title":"Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia","volume":"169","author":"Brodaty","year":"2012","journal-title":"Am J Psychiatry"},{"issue":"10","key":"10.1016\/j.psychres.2020.113641_bib0007","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1111\/jgs.15519","article-title":"Low-Dose Trazodone, Benzodiazepines, and Fall-Related Injuries in Nursing Homes: A Matched-Cohort Study","volume":"66","author":"Bronskill","year":"2018","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.psychres.2020.113641_bib0008","series-title":"Dementia. Australian Prescriber","first-page":"67","article-title":"Pharmacological Treatment of Behavioural Problems","author":"Byrne","year":"2005"},{"issue":"14","key":"10.1016\/j.psychres.2020.113641_bib0009","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/archinternmed.2009.229","article-title":"Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study","volume":"169","author":"Carriere","year":"2009","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.psychres.2020.113641_bib0010","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.encep.2017.02.007","article-title":"[Switching from antipsychotics to aripiprazole and risk of agitation]","volume":"44","author":"Chaumette","year":"2018","journal-title":"Encephale"},{"issue":"3","key":"10.1016\/j.psychres.2020.113641_bib0011","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/YCO.0000000000000594","article-title":"Antipsychotics and the microbiota","volume":"33","author":"Chen","year":"2020","journal-title":"Curr Opin Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2020.113641_bib0012","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1056\/NEJMc062840","article-title":"Hyponatremia associated with escitalopram","volume":"356","author":"Covyeou","year":"2007","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.psychres.2020.113641_bib0013","doi-asserted-by":"crossref","first-page":"253","DOI":"10.14283\/jpad.2018.29","article-title":"Pimavanserin: Potential Treatment For Dementia-Related Psychosis","volume":"5","author":"Cummings","year":"2018","journal-title":"J Prev Alzheimers Dis"},{"issue":"9916","key":"10.1016\/j.psychres.2020.113641_bib0014","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial","volume":"383","author":"Cummings","year":"2014","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.psychres.2020.113641_bib0015","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1177\/0269881117744996","article-title":"Sequential drug treatment algorithm for agitation and aggression in Alzheimer's and mixed dementia","volume":"32","author":"Davies","year":"2018","journal-title":"J Psychopharmacol"},{"issue":"16","key":"10.1016\/j.psychres.2020.113641_bib0016","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1056\/NEJMoa1114058","article-title":"Relapse risk after discontinuation of risperidone in Alzheimer's disease","volume":"367","author":"Devanand","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.psychres.2020.113641_bib0017","first-page":"47","article-title":"Drug treatment of dementia with Lewy bodies and Parkinson's disease dementia\u2013common features and differences]","volume":"34","author":"Drach","year":"2011","journal-title":"Med Monatsschr Pharm"},{"key":"10.1016\/j.psychres.2020.113641_bib0018","article-title":"Intramuscular Olanzapine in the Management of Behavioral and Psychological Symptoms in Hospitalized Older Adults: A Retrospective Descriptive Study","author":"Duong","year":"2015","journal-title":"Journal of aging research 2015"},{"key":"10.1016\/j.psychres.2020.113641_bib0019","unstructured":"FDA, 2008. Information for Healthcare Professionals: Antipsychotics. Available at: htpp:\/\/www.fda.gov\/cder\/drug\/InfoSheets\/HCP\/antipsychotics_conventional.htm.2008."},{"key":"10.1016\/j.psychres.2020.113641_bib0020","series-title":"FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses","year":"2017"},{"issue":"1","key":"10.1016\/j.psychres.2020.113641_bib0021","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/gps.998","article-title":"A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil","volume":"19","author":"Finkel","year":"2004","journal-title":"Int J Geriatr Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2020.113641_bib0022","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.psc.2017.10.010","article-title":"Managing Behavioral and Psychological Symptoms of Dementia","volume":"41","author":"Gerlach","year":"2018","journal-title":"Psychiatr Clin North Am"},{"issue":"1","key":"10.1016\/j.psychres.2020.113641_bib0023","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/HRP.0000000000000197","article-title":"The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An Update on Unipolar Nonpsychotic Depression","volume":"27","author":"Giakoumatos","year":"2019","journal-title":"Harv Rev Psychiatry"},{"issue":"6","key":"10.1016\/j.psychres.2020.113641_bib0024","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/JCP.0b013e31829e8333","article-title":"Acute effects of single-dose olanzapine on metabolic, endocrine, and inflammatory markers in healthy controls","volume":"33","author":"Hahn","year":"2013","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"10.1016\/j.psychres.2020.113641_bib0025","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1177\/1533317511402051","article-title":"Efficacy and tolerability of antidepressants in the treatment of behavioral and psychological symptoms of dementia, a literature review of evidence","volume":"26","author":"Henry","year":"2011","journal-title":"Am J Alzheimers Dis Other Demen"},{"issue":"2","key":"10.1016\/j.psychres.2020.113641_bib0026","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jagp.2019.09.008","article-title":"Efficacy and Safety of ECT for Behavioral and Psychological Symptoms of Dementia (BPSD): A Retrospective Chart Review","volume":"28","author":"Hermida","year":"2020","journal-title":"Am J Geriatr Psychiatry"},{"issue":"11","key":"10.1016\/j.psychres.2020.113641_bib0027","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.jagp.2019.05.002","article-title":"Randomized Placebo-Controlled Trial of Nabilone for Agitation in Alzheimer's Disease","volume":"27","author":"Herrmann","year":"2019","journal-title":"Am J Geriatr Psychiatry"},{"issue":"4","key":"10.1016\/j.psychres.2020.113641_bib0028","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s40266-018-00636-7","article-title":"Pharmacological Management of Dementia with Lewy Bodies","volume":"36","author":"Hershey","year":"2019","journal-title":"Drugs Aging"},{"issue":"1","key":"10.1016\/j.psychres.2020.113641_bib0029","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13104-019-4874-z","article-title":"Anticholinergics and benzodiazepines on cognitive impairment among elderly with Alzheimer's disease: a 1 year follow-up study","volume":"13","author":"Jenraumjit","year":"2020","journal-title":"BMC Res Notes"},{"issue":"10","key":"10.1016\/j.psychres.2020.113641_bib0030","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1007\/s00415-019-09200-8","article-title":"Comparative efficacy and safety of therapy for the behavioral and psychological symptoms of dementia: a systemic review and Bayesian network meta-analysis","volume":"266","author":"Jin","year":"2019","journal-title":"J Neurol"},{"issue":"2","key":"10.1016\/j.psychres.2020.113641_bib0031","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/gps.4470","article-title":"Sleep disturbances are key symptoms of very early stage Alzheimer disease with behavioral and psychological symptoms: a Japan multi-center cross-sectional study (J-BIRD)","volume":"32","author":"Kabeshita","year":"2017","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.psychres.2020.113641_bib0032","doi-asserted-by":"crossref","first-page":"h369","DOI":"10.1136\/bmj.h369","article-title":"Assessment and management of behavioral and psychological symptoms of dementia","volume":"350","author":"Kales","year":"2015","journal-title":"Bmj"},{"issue":"1","key":"10.1016\/j.psychres.2020.113641_bib0033","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1017\/S1041610218000534","article-title":"Management of behavioral and psychological symptoms in people with Alzheimer's disease: an international Delphi consensus","volume":"31","author":"Kales","year":"2019","journal-title":"Int Psychogeriatr"},{"issue":"3","key":"10.1016\/j.psychres.2020.113641_bib0034","article-title":"Reduction in Use of Risperidone for Dementia in Australia Following Changed Guidelines","volume":"7","author":"Kalisch Ellett","year":"2019","journal-title":"Pharmacy (Basel)"},{"issue":"3","key":"10.1016\/j.psychres.2020.113641_bib0035","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/gps.591","article-title":"Hyponatraemia in elderly psychiatric patients treated with Selective Serotonin Reuptake Inhibitors and venlafaxine: a retrospective controlled study in an inpatient unit","volume":"17","author":"Kirby","year":"2002","journal-title":"Int J Geriatr Psychiatry"},{"issue":"4","key":"10.1016\/j.psychres.2020.113641_bib0036","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.annemergmed.2018.04.027","article-title":"Intramuscular Midazolam, Olanzapine, Ziprasidone, or Haloperidol for Treating Acute Agitation in the Emergency Department","volume":"72","author":"Klein","year":"2018","journal-title":"Ann Emerg Med"},{"issue":"6","key":"10.1016\/j.psychres.2020.113641_bib0037","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/gps.636","article-title":"Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer's disease","volume":"17","author":"Lanct\u00f4t","year":"2002","journal-title":"Int J Geriatr Psychiatry"},{"issue":"4","key":"10.1016\/j.psychres.2020.113641_bib0038","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1159\/000077171","article-title":"Frontotemporal dementia: a randomised, controlled trial with trazodone","volume":"17","author":"Lebert","year":"2004","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"7","key":"10.1016\/j.psychres.2020.113641_bib0039","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/archpsyc.60.7.737","article-title":"Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS","volume":"60","author":"Lyketsos","year":"2003","journal-title":"Arch Gen Psychiatry"},{"issue":"5","key":"10.1016\/j.psychres.2020.113641_bib0040","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1176\/appi.ajp.157.5.708","article-title":"Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging","volume":"157","author":"Lyketsos","year":"2000","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2020.113641_bib0041","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/00019442-200002000-00009","article-title":"A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage Alzheimer's disease","volume":"8","author":"Magai","year":"2000","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.psychres.2020.113641_bib0042","unstructured":"Maglione, M., A., R.M., Hu J, W.Z., R., S., PG., S., Roth B, H.L., MJ., S., BA., E., A., M., T., P., 2011. Off-Label Use of Atypical Antipsychotics: An Update. Comparative Effectiveness Review No. 43 (Prepared by the Southern California Evidence-based Practice Center under Contract No. HHSA290-2007-10062-1.) Rockville, MD: Agency for Healthcare Research and Quality. September 2011. Available at: www.effectivehealthcare.ahrq.gov\/reports\/final.cfm."},{"issue":"3","key":"10.1016\/j.psychres.2020.113641_bib0043","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/JCP.0b013e3182900fd6","article-title":"Are low doses of antipsychotics effective in the management of psychomotor agitation? A randomized, rated-blind trial of 4 intramuscular interventions","volume":"33","author":"Mantovani","year":"2013","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"10.1016\/j.psychres.2020.113641_bib0044","doi-asserted-by":"crossref","first-page":"284","DOI":"10.9740\/mhc.2018.11.284","article-title":"Pharmacologic management of behavioral and psychological symptoms of major neurocognitive disorder","volume":"8","author":"Mathys","year":"2018","journal-title":"Ment Health Clin"},{"issue":"1","key":"10.1016\/j.psychres.2020.113641_bib0045","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jalz.2018.06.3063","article-title":"Racial and ethnic estimates of Alzheimer's disease and related dementias in the United States (2015-2060) in adults aged >\/=65 years","volume":"15","author":"Matthews","year":"2019","journal-title":"Alzheimers Dement"},{"issue":"5","key":"10.1016\/j.psychres.2020.113641_bib0046","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1001\/jamapsychiatry.2014.3018","article-title":"Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm","volume":"72","author":"Maust","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"7","key":"10.1016\/j.psychres.2020.113641_bib0047","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1001\/jama.2020.8519","article-title":"Prevalence of Psychotropic and Opioid Prescription Fills Among Community-Dwelling Older Adults With Dementia in the US","volume":"324","author":"Maust","year":"2020","journal-title":"Jama"},{"issue":"1","key":"10.1016\/j.psychres.2020.113641_bib0048","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13670-019-0269-1","article-title":"Pharmacologic Management of Agitation in Patients with Dementia","volume":"8","author":"McDermott","year":"2019","journal-title":"Curr Geriatr Rep"},{"key":"10.1016\/j.psychres.2020.113641_bib0049","series-title":"Preventing overuse of antipsychotic drugs in nursing home care: Safer alternatives","first-page":"1","author":"Metzger","year":"2013"},{"issue":"1","key":"10.1016\/j.psychres.2020.113641_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"issue":"4","key":"10.1016\/j.psychres.2020.113641_bib0051","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19m12828","article-title":"Association of Benzodiazepines and Antidepressants With 180-Day Mortality Among Patients With Dementia Receiving Antipsychotic Pharmacotherapy: A Nationwide Registry-Based Study","volume":"81","author":"N\u00f8rgaard","year":"2020","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.psychres.2020.113641_bib0052","first-page":"1","author":"Osser","year":"2013","journal-title":"Boston MA Copyright Alosa Foundation, Inc"},{"issue":"1","key":"10.1016\/j.psychres.2020.113641_bib0053","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/gps.1828","article-title":"The cannabinoid receptor agonist nabilone for the treatment of dementia-related agitation","volume":"23","author":"Passmore","year":"2008","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.psychres.2020.113641_bib0054","unstructured":"Peskind, E.R., 2015. Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease. https:\/\/ClinicalTrials.gov\/show\/NCT01126099."},{"issue":"11","key":"10.1016\/j.psychres.2020.113641_bib0055","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1097\/JGP.0b013e3180cc1ff5","article-title":"A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia","volume":"15","author":"Pollock","year":"2007","journal-title":"Am J Geriatr Psychiatry"},{"issue":"3","key":"10.1016\/j.psychres.2020.113641_bib0056","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1176\/appi.ajp.159.3.460","article-title":"Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients","volume":"159","author":"Pollock","year":"2002","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2020.113641_bib0057","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/00019442-199705010-00009","article-title":"An open pilot study of citalopram for behavioral disturbances of dementia. Plasma levels and real-time observations","volume":"5","author":"Pollock","year":"1997","journal-title":"Am J Geriatr Psychiatry"},{"issue":"7","key":"10.1016\/j.psychres.2020.113641_bib0058","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1001\/jama.2014.93","article-title":"Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial","volume":"311","author":"Porsteinsson","year":"2014","journal-title":"Jama"},{"issue":"2","key":"10.1016\/j.psychres.2020.113641_bib0059","doi-asserted-by":"crossref","first-page":"190","DOI":"10.4088\/JCP.15m10324","article-title":"High-Dose Citalopram and Escitalopram and the Risk of Out-of-Hospital Death","volume":"78","author":"Ray","year":"2017","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"10.1016\/j.psychres.2020.113641_bib0060","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1176\/appi.ajp.2015.173501","article-title":"The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia","volume":"173","author":"Reus","year":"2016","journal-title":"Am J Psychiatry"},{"issue":"8","key":"10.1016\/j.psychres.2020.113641_bib0061","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.4088\/JCP.v69n0813","article-title":"Missed diagnosis of psychotic depression at 4 academic medical centers","volume":"69","author":"Rothschild","year":"2008","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"10.1016\/j.psychres.2020.113641_bib0062","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/j.pain.0000000000000095","article-title":"Pain, agitation, and behavioural problems in people with dementia admitted to general hospital wards: a longitudinal cohort study","volume":"156","author":"Sampson","year":"2015","journal-title":"Pain"},{"issue":"suppl_1","key":"10.1016\/j.psychres.2020.113641_bib0063","doi-asserted-by":"crossref","DOI":"10.1093\/geront\/gnx167","article-title":"Evidence-Based Nonpharmacological Practices to Address Behavioral and Psychological Symptoms of Dementia","volume":"58","author":"Scales","year":"2018","journal-title":"Gerontologist"},{"issue":"5","key":"10.1016\/j.psychres.2020.113641_bib0064","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/gps.490","article-title":"The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer's disease patients","volume":"17","author":"Schnaider Beeri","year":"2002","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"15","key":"10.1016\/j.psychres.2020.113641_bib0065","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1001\/jama.294.15.1934","article-title":"Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials","volume":"294","author":"Schneider","year":"2005","journal-title":"Jama"},{"issue":"2","key":"10.1016\/j.psychres.2020.113641_bib0066","article-title":"Antidepressants for agitation and psychosis in dementia","author":"Seitz","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.psychres.2020.113641_bib0067","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3233\/JAD-150915","article-title":"Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label, Add-On, Pilot Study","volume":"51","author":"Shelef","year":"2016","journal-title":"J Alzheimers Dis"},{"issue":"7","key":"10.1016\/j.psychres.2020.113641_bib0068","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/gps.1542","article-title":"Comparative efficacy of risperidone versus haloperidol on behavioural and psychological symptoms of dementia","volume":"21","author":"Suh","year":"2006","journal-title":"Int J Geriatr Psychiatry"},{"issue":"1","key":"10.1016\/j.psychres.2020.113641_bib0069","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00019442-199705010-00008","article-title":"A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia","volume":"5","author":"Sultzer","year":"1997","journal-title":"Am J Geriatr Psychiatry"},{"issue":"10","key":"10.1016\/j.psychres.2020.113641_bib0070","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1046\/j.1532-5415.2001.49256.x","article-title":"Does behavioral improvement with haloperidol or trazodone treatment depend on psychosis or mood symptoms in patients with dementia?","volume":"49","author":"Sultzer","year":"2001","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"10.1016\/j.psychres.2020.113641_bib0071","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/bcp.13844","article-title":"Gabapentin and pregabalin to treat aggressivity in dementia: a systematic review and illustrative case report","volume":"85","author":"Supasitthumrong","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.psychres.2020.113641_bib0072","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212508","article-title":"Analgesics in the management of behavioral and psychological symptoms of dementia: a perspective review","volume":"6","author":"Tampi","year":"2017","journal-title":"Drugs Context"},{"issue":"5","key":"10.1016\/j.psychres.2020.113641_bib0073","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/JCP.0b013e31829798d5","article-title":"Efficacy and tolerability of risperidone, yokukansan, and fluvoxamine for the treatment of behavioral and psychological symptoms of dementia: a blinded, randomized trial","volume":"33","author":"Teranishi","year":"2013","journal-title":"J Clin Psychopharmacol"},{"issue":"9","key":"10.1016\/j.psychres.2020.113641_bib0074","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1212\/WNL.55.9.1271","article-title":"Treatment of agitation in AD: a randomized, placebo-controlled clinical trial","volume":"55","author":"Teri","year":"2000","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.psychres.2020.113641_bib0075","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.euroneuro.2013.05.011","article-title":"The cardiovascular safety profile of escitalopram","volume":"23","author":"Thase","year":"2013","journal-title":"Eur Neuropsychopharmacol"},{"issue":"8","key":"10.1016\/j.psychres.2020.113641_bib0076","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/1756285617712979","article-title":"Best practice in the management of behavioural and psychological symptoms of dementia","volume":"10","author":"Tible","year":"2017","journal-title":"Therapeutic advances in neurological disorders"},{"issue":"1","key":"10.1016\/j.psychres.2020.113641_bib0077","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s13063-020-4085-x","article-title":"Use of cannabinoid-based medicine among older residential care recipients diagnosed with dementia: study protocol for a double-blind randomised crossover trial","volume":"21","author":"Timler","year":"2020","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.psychres.2020.113641_bib0078","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/JGP.0b013e3182051bbc","article-title":"Safety and efficacy of electroconvulsive therapy for the treatment of agitation and aggression in patients with dementia","volume":"20","author":"Ujkaj","year":"2012","journal-title":"Am J Geriatr Psychiatry"},{"issue":"4","key":"10.1016\/j.psychres.2020.113641_bib0079","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jagp.2017.09.023","article-title":"Electroconvulsive Therapy for Agitation and Aggression in Dementia: A Systematic Review","volume":"26","author":"van den Berg","year":"2018","journal-title":"Am J Geriatr Psychiatry"},{"issue":"2","key":"10.1016\/j.psychres.2020.113641_bib0080","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1177\/0269881116665357","article-title":"Effects of tetrahydrocannabinol on balance and gait in patients with dementia: A randomised controlled crossover trial","volume":"31","author":"van den Elsen","year":"2017","journal-title":"J Psychopharmacol"},{"issue":"9","key":"10.1016\/j.psychres.2020.113641_bib0081","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.amjmed.2011.12.002","article-title":"Citalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling?","volume":"125","author":"Vieweg","year":"2012","journal-title":"Am J Med"},{"issue":"22","key":"10.1016\/j.psychres.2020.113641_bib0082","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/bdi.12860","article-title":"The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An update on bipolar depression","author":"Wang","year":"2020","journal-title":"Bipolar Disorders"},{"issue":"9","key":"10.1016\/j.psychres.2020.113641_bib0083","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1097\/JGP.0b013e3181ab8c61","article-title":"Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression","volume":"17","author":"Wang","year":"2009","journal-title":"Am J Geriatr Psychiatry"},{"issue":"11","key":"10.1016\/j.psychres.2020.113641_bib0084","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.jagp.2015.05.006","article-title":"Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease","volume":"23","author":"Weintraub","year":"2015","journal-title":"Am J Geriatr Psychiatry"},{"issue":"5","key":"10.1016\/j.psychres.2020.113641_bib0085","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.jemermed.2010.04.012","article-title":"Potential complications of combining intramuscular olanzapine with benzodiazepines in emergency department patients","volume":"43","author":"Wilson","year":"2012","journal-title":"J Emerg Med"},{"issue":"3","key":"10.1016\/j.psychres.2020.113641_bib0086","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/j.2055-2335.2005.tb00348.x","article-title":"Pharmacological treatment of challenging neuropsychiatric symptoms of dementia","volume":"35","author":"Woodward","year":"2005","journal-title":"Journal of Pharmacy Practice and Research"},{"issue":"4","key":"10.1016\/j.psychres.2020.113641_bib0087","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jagp.2012.11.022","article-title":"Dronabinol for the treatment of agitation and aggressive behavior in acutely hospitalized severely demented patients with noncognitive behavioral symptoms","volume":"22","author":"Woodward","year":"2014","journal-title":"Am J Geriatr Psychiatry"},{"issue":"3","key":"10.1016\/j.psychres.2020.113641_bib0088","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.0828","article-title":"Assessment of Reported Comparative Effectiveness and Safety of Atypical Antipsychotics in the Treatment of Behavioral and Psychological Symptoms of Dementia: A Network Meta-analysis","volume":"2","author":"Yunusa","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.psychres.2020.113641_bib0089","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1177\/1533317517749466","article-title":"Helping Dementia Caregivers Manage Medical Problems: Benefits of an Educational Resource","volume":"33","author":"Zimmerman","year":"2018","journal-title":"Am J Alzheimers Dis Other Demen"},{"issue":"6","key":"10.1016\/j.psychres.2020.113641_bib0090","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1176\/appi.ajp.2013.12030408","article-title":"Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg","volume":"170","author":"Zivin","year":"2013","journal-title":"Am J Psychiatry"}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178120333023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178120333023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T05:44:39Z","timestamp":1759038279000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178120333023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":90,"alternative-id":["S0165178120333023"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2020.113641","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An update on management of behavioral and psychological symptoms in dementia","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2020.113641","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113641"}}